Drug Trial Radar · NCT01645332
Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Oct 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Jul 2012
Primary completion
Aug 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Dexa Medica GroupIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-arm, double-blind, parallel, randomized, placebo-controlled clinical study, with 12 weeks of therapy to evaluate the efficacy and safety of DLBS3233 in improving metabolic control in newly diagnosed type-2-diabetic patients, as measured by A1c level, fasting and 2-hours post-prandial plasma glucose, fasting insulin level, HOMA-IR, HOMA-B, adiponectin level, lipid profile, and body weight.
Conditions
- Type-2-diabetes Mellitus
- New Onset
Interventions
Placebo of DLBS3233Drug
Placebo of DLBS3233 once daily for 12 weeks
DLBS3233Drug
100 mg DLBS3233 once daily for 12 weeks
Lifestyle modificationOther
Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of A1c levelTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Endocrinology, Department of Internal Medicine, Dr. Kariadi Hospital
Semarang, Central Java, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.